| Name | Title | Contact Details |
|---|
Pointe Scientific is a Canton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Windsor Health Plan, Inc. is a Medicare Advantage plan with a Medicare contract, and a Medicare-approved Part D Sponsor, whose core purpose is to improve health and well being, peace of mind and financial security for our members when navigating health care coverage options. A partnership between Windsor Health Plan and Sterling Life Insurance Company since 2011, the organization can now provide more resources, member support and plan options for Medicare Advantage beneficiaries and is a leader in the provision of health care to Medicare- and Medicaid-eligible members seeking to enhance their quality of life. Windsor Health Plan manages government sponsored health plans and provides specialty managed care services to insurance providers and to health care providers. Windsor Health Plan is a division of Windsor Health Group, with corporate offices in Atlanta and operational offices in Nashville, Tenn. and Bellingham, Wash., as well as regional offices throughout the United States.
Accuro Medical Products is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Salina Regional Health Center offers rehabilitation services to a wide array of patients. We provide Physical Therapy, Occupational Therapy, Recreational Therapy, Speech Therapy, and Rehabilitation Nursing to many ages.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.